Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Briefs: Link Pharma Chem and Zydus

USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets

HMD Foundation donates iLAB unit to Amrita Hospital Faridabad

With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups

Dabur India expects 10%+ consolidated growth in Q1 FY24

However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.

Aster DM Healthcare increases stake in Malabar Institute of Medical Sciences

Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio